Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

BACKGROUND: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Oncol
Main Authors: Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K. H., Lu, S., Shi, Y., Lee, D. H., Laskin, J., Kim, D.-W., Laurie, S. A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5391700/
https://ncbi.nlm.nih.gov/pubmed/28426106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw611
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares